For Health Care Professionals Outside the US US Residents VOTRIENT Summary of Product Characteristics Safety Information

VOTRIENT is indicated in adults for the first line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.1

Reference: 1. VOTRIENT [summary of product characteristics]. Camberley, UK: Novartis Europharm Limited; February 2018.

Privacy Site Map Contact Us Summary of Product Characteristics Safety Information

Disclaimer: This is an international website for VOTRIENT® (pazopanib) and is intended for health care professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

© 2018 Novartis AG | Use of this website is subject to our Terms of Use